Rosenblum Silverman Sutton S F Inc. CA reduced its stake in shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) by 6.7% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 148,370 shares of the biopharmaceutical company’s stock after selling 10,640 shares during the quarter. Portola Pharmaceuticals comprises approximately 1.3% of Rosenblum Silverman Sutton S F Inc. CA’s portfolio, making the stock its 28th largest holding. Rosenblum Silverman Sutton S F Inc. CA’s holdings in Portola Pharmaceuticals were worth $3,951,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of PTLA. Jackson Square Partners LLC acquired a new position in Portola Pharmaceuticals during the 3rd quarter worth about $26,924,000. BlackRock Inc. lifted its position in Portola Pharmaceuticals by 1.1% during the 3rd quarter. BlackRock Inc. now owns 5,307,407 shares of the biopharmaceutical company’s stock worth $141,335,000 after buying an additional 55,895 shares in the last quarter. Asymmetry Capital Management L.P. lifted its position in Portola Pharmaceuticals by 189.1% during the 3rd quarter. Asymmetry Capital Management L.P. now owns 251,881 shares of the biopharmaceutical company’s stock worth $6,708,000 after buying an additional 164,765 shares in the last quarter. Candriam Luxembourg S.C.A. lifted its position in Portola Pharmaceuticals by 12.8% during the 3rd quarter. Candriam Luxembourg S.C.A. now owns 164,300 shares of the biopharmaceutical company’s stock worth $4,375,000 after buying an additional 18,600 shares in the last quarter. Finally, C WorldWide Group Holding A S lifted its position in Portola Pharmaceuticals by 51.6% during the 3rd quarter. C WorldWide Group Holding A S now owns 223,682 shares of the biopharmaceutical company’s stock worth $5,957,000 after buying an additional 76,095 shares in the last quarter.

Several brokerages recently issued reports on PTLA. Oppenheimer set a $60.00 price target on shares of Portola Pharmaceuticals and gave the stock a “buy” rating in a research report on Sunday, August 26th. MED reduced their price target on shares of Portola Pharmaceuticals from $70.00 to $60.00 and set a “positive” rating on the stock in a research report on Monday, August 27th. ValuEngine upgraded shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, September 1st. Morgan Stanley reduced their price target on shares of Portola Pharmaceuticals from $45.00 to $34.00 and set an “equal weight” rating on the stock in a research report on Monday, August 13th. Finally, Credit Suisse Group reiterated an “underperform” rating and set a $28.00 price target (down previously from $49.00) on shares of Portola Pharmaceuticals in a research report on Friday, August 10th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $42.86.

In other news, Director Jeffrey W. Bird acquired 390,000 shares of the company’s stock in a transaction on Thursday, August 23rd. The stock was purchased at an average cost of $25.84 per share, with a total value of $10,077,600.00. The acquisition was disclosed in a legal filing with the SEC, which is available at this hyperlink. Insiders own 4.60% of the company’s stock.

Shares of NASDAQ:PTLA opened at $19.28 on Wednesday. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -4.01 and a beta of 2.04. Portola Pharmaceuticals Inc has a 1-year low of $18.18 and a 1-year high of $56.70. The company has a debt-to-equity ratio of 1.21, a current ratio of 6.61 and a quick ratio of 6.51.

Portola Pharmaceuticals (NASDAQ:PTLA) last announced its quarterly earnings data on Wednesday, November 7th. The biopharmaceutical company reported ($1.08) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.54) by $0.46. The firm had revenue of $14.20 million during the quarter, compared to analysts’ expectations of $7.10 million. Portola Pharmaceuticals had a negative return on equity of 135.08% and a negative net margin of 1,020.52%. The company’s quarterly revenue was up 270.8% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.41) EPS. As a group, sell-side analysts expect that Portola Pharmaceuticals Inc will post -5.03 EPS for the current year.

COPYRIGHT VIOLATION NOTICE: This report was posted by Daily Political and is the property of of Daily Political. If you are reading this report on another publication, it was illegally stolen and republished in violation of US and international trademark & copyright law. The original version of this report can be accessed at https://www.dailypolitical.com/2018/11/21/rosenblum-silverman-sutton-s-f-inc-ca-decreases-position-in-portola-pharmaceuticals-inc-ptla.html.

About Portola Pharmaceuticals

Portola Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics that could advance the fields of thrombosis and other hematologic diseases. The company's two FDA-approved medicines are Andexxa (coagulation factor Xa (recombinant), inactivated-zhzo), an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of VTE in adult patients hospitalized for an acute medical illness.

Recommended Story: What is the S&P 500 Index?

Want to see what other hedge funds are holding PTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Portola Pharmaceuticals Inc (NASDAQ:PTLA).

Institutional Ownership by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.